Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

40.09 -0.58 (-1.41%)
Streaming Delayed Price Updated: 11:07 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
From Guardant Health, Inc.
Via Business Wire
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Guardant Health Earnings Perspective: Return On Capital Employed
Via Benzinga
Looking Into Guardant Health's Return On Capital Employed
Via Benzinga
FTC Orders Biotech Illumina To Unwind Grail Deal Amid Icahn Battle
The FTC ordered Monday that biotech firm Illumina must unwind its $8 billion purchase of the cancer-testing startup Grail. ILMN stock fell. 
Via Investor's Business Daily
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
From Guardant Health, Inc.
Via Business Wire
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
From Guardant Health, Inc.
Via Business Wire
Analyst Expectations for Guardant Health's Future
Via Benzinga
Earnings Outlook For Guardant Health
Via Benzinga
2 Stocks That Could Rebound and Rise 30% or More in 2023
They're down, but they aren't yet out. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
Via Benzinga
2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull Market
Investing now is an admittedly risky bet, but the payoff could be massive. 
Via The Motley Fool
Musa Tariq Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming March Investor Conferences
From Guardant Health, Inc.
Via Business Wire
25 AI Stocks to Buy Right Now
Looking to benefit from the AI boom started by ChatGPT? Here are the best AI stocks to buy for the emerging market frenzy. 
Via InvestorPlace
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
From Guardant Health, Inc.
Via Business Wire
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. Schrödinger is a... 
Via Talk Markets
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
From Guardant Health Inc.
Via Business Wire
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Guardant Health, Inc.
Via Business Wire
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
From Guardant Health, Inc.
Via Business Wire
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
From Guardant Health, Inc.
Via Business Wire
Down 40% in 2022, Can Exact Sciences Recover in 2023?
Investors are attracted to its leading position in the market for early cancer detection, but the persistent losses its been reporting are enough to make anyone nervous. 
Via The Motley Fool
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
From Guardant Health, Inc.
Via Business Wire
Cathie Wood Makes This Molecular Diagnostics Company Top Holding Of Ark Invest's Flagship Fund, Catapulting Past Zoom, Tesla
Shares of Exact Sciences, Inc. (NASDAQ: EXAS) have been on a tear, having gained over 27% in two sessions this week. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.